FDA Approves Bristol-Myers Squibb Sanofi-Synthelabo Partnership's Avapro to Lower Hypertension
Avapro is in a group of drugs called angiotensin II receptor antagonists.
It keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. It works by decreasing the levels of certain chemicals in the body.
Avapro is used to treat high blood pressure. It is sometimes given together with other blood pressure medications.
Avapro is also used to treat kidney problems caused by type 2 (not insulin-dependent) diabetes.
Avapro is used to treat high blood pressure. A member of the new family of drugs called angiotensin II receptor antagonists, it works by preventing the hormone angiotensin II from narrowing the blood vessels, an action that tends to raise blood pressure. Avapro may be prescribed alone or with other blood pressure medications.
In people with type 2 diabetes and high blood pressure, Avapro is also prescribed to stave off damage to the kidneys, often delaying the need for dialysis and a kidney transplant.
This drug is used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes. High blood pressure reduction helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the hormone angiotensin thereby relaxing blood vessels, causing them to widen. Irbesartan belongs to a class of drugs called angiotensin receptor blockers.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for the antihypertensive agent AVALIDE for initial use in patients with hypertension who are likely to need multiple drugs to achieve their blood pressure goals.
The approval is based on data from two clinical trials involving more than 1,200 patients with moderate or severe high blood pressure.